Rapamycin and Chloroquine Modulate Insulin Resistance and Hepatic Steatosis in a High-Fat/High-Cholesterol Diet-Induced Metabolic Dysfunction-Associated Steatotic Liver Disease Mouse Model
Open Access
- 1 November 2025
- journal article
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 18, 4059-4072
Abstract
Objective: To establish a short-term high-fat/high-cholesterol (HFHC) diet-induced Metabolic dysfunction-associated steatotic liver disease (MASLD) mouse model, and evaluate the effects of rapamycin (RaPa) and chloroquine (CQ) on this model to explore their therapeutic potential and side effects. Methods: An early MASLD mouse model was constructed via short-term HFHC diet feeding. Model mice were intraperitoneally injected with RaPa or CQ. Drug effects were analyzed on body weight, liver weight, lipid metabolism-related genes (APOB, FASN, PLIN2), inflammatory factors (IL-6, IL-10), and fibrosis markers (LOX, Col-1α-1, CCL2, TGFβ1, PDGFRβ, α-SMA) at mRNA and protein levels. Results: RaPa ameliorated body weight and liver weight in early MASLD mice, downregulated FASN and PLIN2 expression, upregulated IL-10 mRNA levels, and alleviated hepatic steatosis, but induced metabolic disorders such as Insulin resistance and hyperlipidemia. In contrast, CQ promoted FASN and PLIN2 expression, exacerbated hepatic steatosis, reduced IL-10 mRNA levels, and upregulated fibrosis-related markers (LOX, TGFβ1, PDGFRβ, α-SMA) at both mRNA and protein levels, thereby driving MASLD progression to liver fibrosis. Notably, CQ improved metabolic abnormalities in model mice, including obesity, hyperlipidemia, and Insulin resistance. Conclusion: RaPa and CQ exhibit dual effects on early MASLD: RaPa alleviates hepatic steatosis but exacerbates metabolic disorders, whereas CQ improves metabolic abnormalities but accelerates liver fibrosis. This paradox highlights the need to balance metabolic regulation and liver injury prevention in MASLD treatment, providing critical experimental insights for targeted drug development.Keywords
This publication has 40 references indexed in Scilit:
- Role of autophagy in betaine-promoted hepatoprotection against non-alcoholic fatty liver disease in miceCurrent Research in Food Science, 2023
- Hepatocyte CHRNA4 mediates the MASH-promotive effects of immune cell-produced acetylcholine and smoking exposure in mice and humansCell Metabolism, 2023
- Nonalcoholic SteatohepatitisJAMA, 2020
- Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver FibrosisHepatology, 2020
- Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart DiseaseJAMA, 2019
- Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trialDiabetologia, 2015
- Severity of non-alcoholic fatty liver disease is associated with high systemic levels of tumor necrosis factor alpha and low serum interleukin 10 in morbidly obese patientsClinical and Experimental Medicine, 2015
- Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitisHepatology, 2012
- Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivityJournal of Molecular Medicine, 2011
- Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patientsArthritis Care & Research, 2010